Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Pyrithioxin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1980

A placebo-controlled study of pyritinol ('Encephabol') in dementia.

A double-blind, placebo-controlled trial was carried out on 40 patients suffering from moderately advanced dementia. The patients were allocated randomly either pyritinol (800 mg daily) or identical placebo for 3 months. Assessments using a modified Crichton Geriatric Behavioural Rating Scale were made pre-treatment and monthly up to 3 months, and then at follow-up at 6 months. Patients on pyritinol showed significantly higher levels of improvement than did those on placebo. Laboratory tests conducted throughout remained within normal limits for both groups.

Aged↗
PubMed1982

[Correlations between biological and clinical indices in children with intellectual deficiencies].

Some biochemical and electrophysiological parameters were examined in 20 intellectually-defective children with a history of pre- and perinatal damages. Certain correlations between the character of EEG changes, the level of amino acids in the peripheral blood, and the efficacy of treatment with drugs acting upon metabolism were discovered. A marked slow-wave activity was observed on the EEG in the group of patients whose clinical course was the most unfavourable: this activity coincided with an elevated level of methionine (the source of the methyl groups in acetylcholine biosynthesis) in the peripheral blood. The therapeutic effect was the most marked in children with paroxysmal EEGs: this was accompanied in them with an increased content of functional amino acids. The data obtained are important for a more differentiated approach to the therapy of mentally retarded patients.

Amino Acids↗
PubMedDate not supplied

[Comparative evaluation of the therapeutic effectiveness of drugs of different mechanisms of action in cerebral atherosclerosis].

The author describes the results of treatment of 299 patients with clinical evidence of cerebral atherosclerosis receiving three groups of antiatherosclerotic agents: improving cerebral blood flow (naftidrofuryl, cinnarazine, pyridinol carbamate, low-molecular dextran), normalizing lipid metabolism (clofibrate, heparinoid, alpha-tocopherol, Procetophen) and improving the metabolism of nerve cells (piracetam, pyritinol). After a statistical analysis of the results of the author evaluated the effectiveness of these drugs in various groups and suggested practical conclusions and treatment schedules in various forms of cerebral atherosclerosis.

Anticholesteremic Agents↗
PubMedDate not supplied

JPC-80, a new slow acting antirheumatoid drug.

JPC-80 has been administered to man for the first time. Twelve patients received doses up to 300 mg daily for up to 12 weeks. Three suffered significant, but not serious, side effects: 1 skin rash, 1 elevation of liver enzymes, 1 diarrhea. All signs or symptoms returned to normal on discontinuation of drug. Four of 8 patients receiving cumulative doses of over 20 g showed moderate or major improvement. In patients with clinical improvements the mean erythrocyte sedimentation rate fell from 51 to 21, and rheumatoid factor titers fell from 1444 to 647. This pilot study justifies additional controlled studies.

Adult↗
PubMed1981

Tamitinol in paedopsychiatric out-patient therapy.

A study was carried out in 11 children, ranging in age from 7 to 12 years, to determine the clinical effect of tamitinol, in addition to psychotherapy, in alleviating disturbances of learning and behaviour. Tamitinol was administered as one 100 mg tablet per 10 kg body weight daily for 8 weeks. Assessments were made of the patients' mental condition using a 7-point rating scale, before and during treatment. Global response to treatment and tolerance were evaluated at the end of the trial by the clinician and the patients (or parents). Significant improvement was noted in 7 of the 10 children who completed the study. Six of the 13 psychiatric symptoms evaluated by the clinician were significantly improved (p less than 0.01). The drug was well tolerated by all patients.

Body Weight↗
PubMedDate not supplied

[Two cases of superficial pemphigus induced by pyritinol (author's transl)].

Pyritinol is presently prescribed in rhumatoid polyarthritis because of its structural analogy to D-penicillamin. Only benign cutaneous side effects had been mentioned up to now. We report two cases of pemphigus occurring during pyritinol therapy given in one case for rhumatoid polyarthritis, in the other case for memory deficiency. Clinical aspect was that of a superficial pemphigus. The histologic picture was in some instances that of a superficial acantholysis, and in other instances, that of an eosinophilic spongiosis. Definite proof of pemphigus was shown by presence of anti-intercellular substance antibodies in the serum and in the skin of both patients.

Aged↗
PubMedDate not supplied

The influence of the administration of pyritinol on the clinical course of traumatic coma.

(1) In a total of 100 patients with traumatic coma who were admitted to the intensive care unit of our Department of Neurosurgery we examined the effect of Encephabol after intravenous administration. (2) Compared to patients with the same clinico-neurological conditions who were, however, not treated with Encephabol, the cases treated by the preparation did not show any significant clinical improvement. Moreover, in the Encephabol group mortality rate in patients with an unfavourable prognosis sank to 35.3% (mortality rate in the comparative group: 54.2%). (3) Untoward effects on the clinico-neurological condition, cortical electrogenesis, vegetative functions and body fluid parameters were not observed after administration of the preparation.

Adolescent↗